p RESENTLY, hypervolemic therapy with albuminates and/or induced hypertension is an accepted treatment for a delayed ischemic deficit that develops after aneurysmal subarachnoid hemorrhage (SAH). Hypervolemic therapy is intended to increase cerebral tissue perfusion, but it may also aggravate vasogenic edema when the blood-brain barrier (BBB) is impaired by severe tissue ischemia. 2j'22 Several investigators have warned against the danger of hemorrhagic infarction that may result from continuing induced hypertension after a delayed ischemic deficit resolvesJ 5 '23 The present study was undertaken to investigate whether the intracranial complications that result from hypervolemic therapy can be predicted clinically and neurologically, and to determine when hypervolemic therapy may be prescribed with optimum benefit.
Clinical Material and Methods

Case Material
At Tokai University Hospital and its affiliated hospital, 323 patients with SAH were admitted during the 7 89 period from January, 1984, to June, 1991. Of these, 65% (211 patients) did not develop a delayed ischemic deficit. Hypervolemic therapy was instituted only after the onset of an ischemic deficit. Of the 112 patients who did develop a delayed ischemic deficit, 94 were managed with hypervolemic therapy (47 with a conventional regimen and 47 with an "optimum" regimen). Of these 94 patients, 71 had undergone obliteration of the aneurysm neck within 3 days after SAH (Table 1) . Those patients who developed a delayed ischemic deficit were classified into one of four groups as follows: 1) patients who received hypervolemic ther- outcome  excellent  41  0  0  1  good  14  1  1  3  poor  2  2  2  3  vegetative  0  1  0  2  dead  11  14  5 9 * WFNS = World Federation of Neurological Surgeons; 5 early op = early aneurysm neck obliteration within 3 days after subarachnoid hemorrhage; ICH = intracerebral hemorrhage; CT = computerized tomography. Significance was determined according to the chisquared test: t = P < 0.05; ~ = p < 0.01. w Immediate clinical improvement by hypervolemic therapy.
[I The 14 patients who died within 3 days after hypervolemic therapy are excluded. apy but had no intracranial complication; 2) patients who received hypervolemic therapy and in whom brain edema was aggravated; 3) patients who received hypervolemic therapy and developed a hemorrhagic infarct; 4) patients who did not receive hypervolemic therapy because massive infarction and/or edema was seen on the computerized tomography (CT) scan obtained at the time their delayed ischemic deficit was manifested.
Terminology
The clinical grade of each patient was determined on admission according to the World Federation of Neurological Surgeons' grading system? Every patient who underwent aneurysm neck obliteration within 3 days after SAH also had CT within 24 hours of surgery irrespective of any clinical change.
The diagnosis of a delayed ischemic deficit was based on the development of a focal neurological abnormality after recovery from the initial SAH and when CT scan showed neither rebleeding nor hydrocephalus.~~ When neurological deterioration was not focal, we ruled out a metabolic disturbance such as hypoxia or hyponatremia and immediately obtained an angiogram to confirm arterial narrowing.
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Contusions and edema that developed in the brain parenchyma underneath the surgical retractor were considered. Infarction that resulted from occlusion of the parent artery, or perforation by an aneurysm clip were also regarded as a surgical complication. Patients with intracerebral hemorrhage (ICH) due to primary aneurysm rupture were excluded from this group.
Palient Management
Conventional tf ypervolemic Therapy. "Conventional hypervolemic therapy" was provided by continuous intravenous drip infusion of albuminates, fresh frozen plasma, low-molecular-weight dextran, and glycerol in 47 cases with the goal of maintaining the hematocrit at 30 ml/dl. In each of these patients, the hemodynamic parameters were maintained as follows: pulmonary, capillary wedge pressure (PCWP) 8 to 12 mm Hg and central venous pressure (CVP) 8 to 12 cm H_~O. In patients who did not undergo early aneurysm surgery, the hemodynamic parameters were maintained as follows: PCWP 6 to I0 mm Hg; CVP 6 to 10 cm H20; and systemic blood pressure below 180 mm Hg.
Optimum Hypervolemic Therapy. In the 47 cases treated most recently by hypervolemia, we provided "optimum hypervolemic therapy" while monitoring hemodynamic parameters by a Swan-Ganz catheter, irrespective of whether early aneurysm surgery had been performed. The hematocrit was maintained at 30 ml/ dl in this group as well. In this protocol, the PCWP and/or CVP was increased immediately by the rapid injection of the same fluids as used in conventional hypervolemic therapy until the neurological deficit was reversed. Then the patient was observed closely for any neurological change. The hemodynamic profile that was associated with neurological improvement, rather than a predefined profile, was defined as the optimum profile for that patient. The hemodynamic parameters were then maintained at the optimum values until they could be decreased without reappearance of the neurological deficit. In patients who were not operated on, every attempt was made to discontinue hypervolemic therapy as soon as possible; however, control of systemic blood pressure was not achieved in any of these patients. 
Evaluation of Edema and Hemorrhagic Infarction
A low-density area around an infarction on CT, an ICH, or a contusion (caused by surgical manipulation) was considered to represent brain edema in this study. An increase in brain edema was discerned by comparing a follow-up CT scan to the one obtained immediately after the onset of the delayed ischemic deficit. * Patients who had intracerebral hemorrhage due to primary aneurysm rupture are excluded. Significance was determined according to the chi-squared test: t = P < 0.05; ~ = p < 0.01.
w Some patients had more than two different surgical complications. * ICH = intracerebral hemorrhage due to primary aneurysm rupture. Significance was determined according to the chi-squared test: t = P < 0.05.
A hemorrhagic infarction was diagnosed by identifying a hemorrhagic lesion within a previously identified infarct on the CT scan. This was attributed to hemodilution and hypervolemia only if this hemorrhage appeared after initiation of therapy.
Statistical Analysis
Data from the patient groups were compared using the chi-squared test or non-paired t-test.
Results
Clinical Features on Admission
Among the 112 patients who developed a delayed ischemic deficit after SAH, 94 patients (84%) were treated with hypervolemic therapy and 18 (16%) were not. Among the patients who received hypervolemic therapy, 68 patients (72%) experienced no intracranial complication, 18 (19%) exhibited aggravation of the brain edema, and eight (9%) developed a hemorrhagic infarction ( Table 1) .
The clinical grade of, the patients did not differ significantly between those who experienced an intracranial complication of hypervolemic therapy and those who experienced no such complication ( Table 1 ). The FIG. 1. Correlation between the type of intracranial complication that developed after hypervolemic therapy and the day after subarachnoid hemorrhage when the delayed ischemic deficit was manifested.
incidence of ICH on admission CT scans in each group did not differ significantly (Table 1 ).
Postoperative CT Findings
The frequency of early obliteration of the aneurysm neck (within 3 days after SAH) in each group is shown in Table 1 and did not differ significantly among the groups. Postoperative abnormal CT findings, such as a brain contusion, edema, or infarction, which presumably resulted from surgical manipulation, are shown in Table 2 (patients who had ICH due to primary aneurysm rupture are excluded). No patient with a postoperative hemorrhage was found in either hypervolemic therapy group; however, two of the 18 patients managed without hypervolemia suffered SAH after surgery.
In the 18 patients whose brain edema was aggravated, contusion, edema, and infarction were significantly more frequent than in those who experienced no intracranial complication from hypervolemia ( Table 2 ). In contrast, patients who experienced a hemorrhagic infarction did not differ significantly from those patients who experienced no intracranial complication from hypervolemia. The 18 patients who received no hypervolemic therapy exhibited contusion, edema, or infarction more frequently and resembled those in whom brain edema was aggravated ( Table 2) . Table 3 summarizes the complications in the patients with ICH due to primary aneurysm rupture. Aggravation of brain edema by hypervolemic therapy was found more frequently in those patients with postoperative massive edema.
Onset of Delayed Ischemic Deficit and the Type of Complication
The interval between the SAH and the onset of a delayed ischemic deficit is shown in Fig. 1 . Of the 68 patients who experienced no intracranial complication after hypervolemic therapy, 65% manifested the delayed ischemic deficit on or after the 7th day following their SAH. Of the 18 patients whose brain edema was exacerbated by hypervolemic therapy, 72% developed the delayed ischemic deficit within 6 days after their SAH. In contrast, the delayed ischemic deficit developed on or after 7 days post-SAH in all eight patients who had a hemorrhagic infarction (Fig. 1) . The incidence of delayed ischemic deficits developing within 6 days after an SAH was 44% in the 18 patients who received no hypervolemic therapy.
CT Findings at Onset of Delayed Ischemic Deficit
In 17 (25%) of 68 patients who experienced no intracranial complication from hypervolemia, a new infarct due to a delayed ischemic deficit was found on a CT scan obtained at the time the delayed ischemic deficit was manifested; however, the infarct was localized and small in 16 of these 17 patients. There was a new infarct which was evident on a CT scan obtained at the time the delayed ischemic deficit developed in nine (50%) of 18 patients who experienced aggravation of their brain edema, in all eight patients who developed a hemorrhagic infarction, and in 10 (56%) of 18 patients who received no hypervolemic therapy. Many of those patients' infarcts were massive (Fig. 2) .
Brain edema, which was seen occasionally on CT scans obtained at the time of delayed ischemic deficit, was not necessarily related to the deficit and may have M. Shimoda, et al.
resulted from other causes such as postoperative contusion, edema, or infarction. Only seven (10%) of 68 patients with no intracranial complication from hypervolemia had a localized area of edema on CT. In contrast, the incidence of edema at the time of the ischemic deficit in other groups was as high as 61% to 100%. In the majority of those patients, the edema was extensive and exerted a mass effect, particularly in those patients who had edema that was aggravated by the therapy (88% incidence of edema; edema exerted a mass effect in 15 of 16) (Fig. 2) .
Clinical Course After ttypervolemic Therapy
Clinical improvement was seen initially in each hypervolemic therapy group. Improvement was seen in 85% of patients with no intracranial complication from hypervolemia; in 61% of patients with aggravation of brain edema; and in 38 % of patients with a hemorrhagic infarction. The incidence of improvement in the latter two groups was significantly lower than in the remainder ( Table 1) .
All 18 patients with aggravation of brain edema deteriorated rapidly, and eight patients (44%) were brain-dead within 24 hours after hypervolemic therapy. Ultimately, a total of 14 patients (78%) died. The mortality rate was lower (50%) and the excellent outcome better (22 %) in the 18 patients who did not receive hypervolemic therapy because of the identification of a large area of infarction on the CT scan at the time the neurological deficit became apparent.
In seven of eight patients with a hemorrhagic infarction, the time to deterioration was 3 to 7 days after initiation of hypervolemic therapy (Table 4 ) and 8 to 17 days after the SAH (the time when a delayed ischemic deficit typically resolves). In the exception, a hemorrhagic infarction developed within 24 hours after optimum hypervolemic therapy was begun, and was most likely caused by a coagulopathy that arose from the administration of low-molecular-weight dextran for hemodilution. With the exception of two cases, the lesions arose in subcortical areas. Multiple lesions were seen in only two of eight patients ( Table 4 ). The prognosis of these patients was unfavorable: five (63%) of the eight died. Intracranial complications of hypervolemic therapy Ultimately, after receiving hypervolemic therapy, the incidence of ischemic infarction due to vasospasm was: 37% (25 of 68 cases) for patients who had no intracranial complication from hypervolemia; 100% (four cases) for patients in whom brain edema was aggravated (14 patients who died within 3 days after hypervolemic therapy were excluded); 100% (eight cases) for patients who developed a hemorrhagic infarction; and 72% (13 of 18 cases) for patients who received no hypervolemic therapy ( Table 1 ). The total incidence of ischemic infarction among those who presented with SAH, excluding the 24 who were brain-dead within 3 days after their SAH, was 17% (50 of 295 cases).
Comparison of the Two Hypervolemia Regimens
Brain edema was aggravated in 12 (26%) of 47 patients who received conventional hypervolemic therapy, and in six (13%) of 47 patients who received optimum hypervolemic therapy. Of eight patients who developed hemorrhagic infarction after hypervolemic therapy, two (4%) had been treated with optimum hypervolemic therapy and six (13%) had been treated with conventional hypervolemic therapy ( Table 5 ).
The incidence of ischemic infarction on CT scans, due to vasospasm and pulmonary edema, was higher in patients who received conventional hypervolemic therapy. The favorable outcome rate (excellent and good) was 47% (22 cases) for patients who received conventional hypervolemic therapy, and significantly higher (74%, 35 cases) for patients who received optimum hypervolemic therapy (Table 5 ). ~t Patients who became brain-dead within 3 days after hypervolemic therapy are excluded.
Discussion
Rationale for tfypervoh, mic Therapy
Hypervolemic therapy and/or induced hypertension are the most prevalent therapies for patients who develop a delayed ischemic deficit after SAH. 6'9AL '16"17 Cerebral autoregulation is impaired in SAH patients, primarily due to cerebral vasospasm. 25 Accordingly, the rationale underlying the treatment is to increase the cerebral perfusion pressure and cerebral blood flow (CBF) to the ischemic areas. At the very least, correcting hypovolemia to normovolemia is important therapeutically in managing delayed ischemic deficits because cardiac output and CBF are coupled in hypovolemia 4 and because circulating blood volume is depressed in SAH. 18 Meanwhile, several reports emphasize that CBF is increased as intravascular volume is expanded by albuminate because blood viscosity is decreased rather than because cardiac output is increased, z826 Several investigators have noted that nondilutional hypervolemia neither improves collateral perfusion to ischemic regions nor mitigates infarction 3~ and that isovolemic hemodilution elevates the CBF without increasing oxygen transport. 8~2627 Dilutional hypervolemia is thought to improve ischemia by decreasing blood viscosity, and thereby improving collateral perfusion. Resistance to flow is then decreased further as oxygen transport is improved. Any reduction in blood viscosity suggests that a direct relationship always exists between CBF and cardiac output in the ischemic brain. 2~' 2z28-3~
Risk of Hypervolemic Therapy
Several investigators consider that hypervolemic therapy is ineffective and could be harmful. They believe that, in the experimentally damaged brain, hypervolemic therapy 1) increases BBB permeability; 2) aggravates vasogenic edema; 3) increases intracranial pressure (ICP); 4) decreases CBF by so-called "false autoregulation," and 5) does not modify the evolution of an infarction. 3'2'4'9 Furthermore, Wood, et al., 29 reported that ICP is elevated by any increase in cerebral blood volume that results when cerebrovascular resistance is reduced by hypervolemic hemodilution. This is not likely to be secondary to any increase in brain water content but may result from an increase in cerebral blood volume.
Analysis of Current Study
In clinical investigations of SAH patients, Yamakami, et al., 32 reported that volume expansion did not change the CBF in patients with a delayed ischemic deficit. They concluded that the detrimental effects of volume expansion may overwhelm the benefits in patients with a delayed ischemic deficit who may have a damaged BBB and increased cerebral blood volumef Thus, the efficacy of hypervelemic therapy is determined by the balance between improvement in the microcirculatory flow and impediment to this flow by local edema? ~ Accordingly, this balance must be considered in determining the indications for hypervolemic therapy.
Several authors who advocate hypervolemic therapy restrict its clinical indications and proceed conservatively. Specifically, they measure ICP during volume expansion, 24 do not treat patients with significant cerebral edema, increased ICP, or brain infarction] ' 16 and avoid treating those for whom treatment is being considered too late? 1' 22' 25 Sundt, et al., 2~ emphasized that hemodilution may be harmful when the ischemic area is large because the increase in edema would also be large. Voldby, et al., 25 claimed that methods which safely increase cerebral perfusion pressure, such as cerebrospinal fluid drainage and/or hyperventilation, should be chosen prior to other treatments.
In the present study, the majority of patients in whom brain edema was aggravated by hypervolemic therapy developed a delayed ischemic deficit within 6 days after SAH before the resolution of brain edema, due either to surgical intervention and/or to the primary damage caused by the SAH. At the time of the delayed ischemic deficit, radiographic manifestations of a new infarct were found on CT in one-half of the cases; however, in one-half of these cases the findings were localized. In patients with no intracranial complication, a new infarct was found on follow-up CT in 26%. This is a surprisingly high number, but in 17 of these 18 cases the lesions were localized. We suggest that, unlike a massive infarction, a small localized infarct documented on the CT when a delayed ischemic deficit is manifested should not contraindicate hypervolemic therapy. In contrast, extensive edema, especially that which exerts a mass effect and increases the ICP, should be considered a strong contraindication to hypervolemic therapy. Prognosis is poor regardless of therapy, but the results in those who underwent hypervolemic therapy were devastating. In conclusion, we believe that hypervolemic therapy may be harmful when multiple abnormalities such as infarction, brain edema, or elevated ICP are evident at the time a delayed ischemic deficit is manifested. These issues should be considered in every patient irrespective of the method of hypervolemic therapy.
Hemorrhagic Infarction Attributable to Hypervolemic Therapy
In the literature, the incidence of hemorrhagic infarction after vasospasm is reported to be 32% to 35% ~5' 23 and the complication occurs usually during recovery from vasospasm. ~5' 23 Ohta, et al., ~5 attributed this phenomenon to the relative increase in CBF that occurs as vasospasm resolves and which in turn increases vascular permeability. However, it seems unlikely that any one CT or clinical finding could predict hemorrhagic infarction and be reliable enough to contraindicate hypervolemic therapy.
To prevent hemorrhagic infarction after hypervolemic therapy, it is extremely important that hypervolemic therapy be discontinued as soon as possible after the delayed ischemic deficit resolves. It is, therefore, also important to determine precisely the time when a delayed ischemic deficit resolves. In managing delayed ischemic deficits, it is important to establish the optimum for each hemodynamic parameter. If hemody-namic parameters are changed during the course of treatment and a neurological deficit reappears, one should act as though the delayed ischemic deficit has not resolved. On the other hand, if a neurological deficit does not reappear as hemodynamic parameters are changed, the patient should be treated as though the delayed ischemic deficit is resolving and one should immediately discontinue volume expansion completely. It is our present opinion that, when properly administered and if discontinued promptly after a delayed ischemic deficit resolves, optimum hypervolemic therapy can prevent hemorrhagic infarction.
Ideal Hypervolemic Therapy Regimen
A recent article by the Illinois group 13 reported that prophylactic hypervolemia for SAH patients in a good clinical grade was not effective and was associated with pulmonary edema in 26% due to volume expansion. In their prophylactic hypervolemia protocol, they began volume expansion on the day of surgery and maintained each hemodynamic parameter in the same range as that used in our conventional hypervolemic therapy protocol. As stated above, we believe that hypervolemic therapy may be very harmful in the early phase after SAH and before the development of brain edema due either to surgical intervention and/or to the primary brain damage. Indeed, volume balance should be negative to facilitate the early improvement of edema. Furthermore, conventional hypervolemic therapy makes it difficult to determine when a delayed ischemic deficit is resolving and may cause therapy to continue unnecessarily long at either above or below the true optimum hemodynamic profile required to maintain cerebral perfusion. Additionally, it may increase the incidence of pulmonary edema in patients who received conventional hypervolemic therapy. Accordingly, we found optimum hypervolemic therapy to be more successful than conventional hypervolemic therapy. If one excludes retrospectively those patients for whom optimum hypervolemic therapy was not indicated, the favorable outcome rate becomes 85% (35 of 41 patients), a surprisingly high number for patients who develop a delayed ischemic deficit after SAH. We conclude that, when provided as indicated, optimum hypervolemic therapy is a successful treatment for delayed ischemic deficit subsequent to SAH.
